Calderasib (MK-1084)

[DATA NOTE: This writeup covers calderasib (MK-1084) and was erroneously assigned to node pipeline-leucovorin-levofolinate. Leucovorin is a decades-old generic folate compound that appears here only as a background component of the mFOLFOX6 chemotherapy regimen - it is not the investigational drug. This content should be reassigned to a calderasib/MK-1084 pipeline node, and the leucovorin-levofolinate node should be audited for deletion or reclassification as a non-pipeline background agent.] Calderasib (MK-1084) is Merck's covalent KRAS G12C inhibitor being tested in KANDLELIT-012 (NCT06997497), a Phase 3 trial combining it with cetuximab and mFOLFOX6 chemotherapy as first-line treatment for KRAS G12C-mutant metastatic colorectal cancer [1]. This trial matters because existing KRAS G12C inhibitors - sotorasib and adagrasib - are approved only in the chemorefractory (later-line) setting [2][3]. If KANDLELIT-012 succeeds, it would establish targeted KRAS G12C therapy as a front-line standard of care, a much larger commercial opportunity.

Calderasib is a novel compound with no approvals anywhere. The KANDLELIT-012 trial was initiated in early 2025, targeting enrollment of approximately 462 patients. It evaluates the triple combination of calderasib plus cetuximab (an anti-EGFR antibody) plus mFOLFOX6 (the standard chemo backbone of oxaliplatin, leucovorin, and 5-fluorouracil) [1]. No FDA designations - breakthrough therapy, fast track, or orphan - have been disclosed for calderasib in CRC as of early 2026. Merck has a parallel Phase 3 program in NSCLC: KANDLELIT-004 tests calderasib plus pembrolizumab in PD-L1-high NSCLC, and KANDLELIT-007 adds the same combination with the subcutaneous Keytruda QLEX formulation [4][5]. The NSCLC program is arguably further ahead in terms of commercial potential, given the 77% response rate seen with the calderasib-pembrolizumab doublet in treatment-naive PD-L1 TPS ≥1% patients (n=69, median follow-up 12.1 months) at Phase 1 [14][15]. Readout timing for KANDLELIT-012 has not been publicly disclosed, but given typical Phase 3 CRC enrollment and PFS endpoint maturation, a primary analysis before late 2027 or 2028 would be optimistic. A key competitive timeline: Mirati/BMS's KRYSTAL-10 Phase 3 trial is testing adagrasib plus cetuximab versus chemotherapy in second-line KRAS G12C mCRC, with readout expected in 2026 [16]. If KRYSTAL-10 succeeds, it could establish the KRAS G12C inhibitor plus anti-EGFR paradigm as a post-chemotherapy standard before KANDLELIT-012 reports. The CRC indication is smaller than NSCLC - KRAS G12C mutations occur in only about 3-4% of colorectal cancers - but the front-line positioning, if successful, would capture patients before they ever reach sotorasib or adagrasib.

KRAS is a protein that acts like an on/off switch for cell growth. When working normally, KRAS flips on briefly to tell cells to divide, then flips back off. The G12C mutation - a single amino acid change at position 12 from glycine to cysteine - jams the switch in the 'on' position, forcing cells to grow nonstop [7]. For decades, KRAS was called 'undruggable' because the protein's surface is smooth with no obvious pocket for a drug to grab onto. The breakthrough came from discovering that the G12C mutation creates an exposed cysteine residue - essentially a chemical hook - that a drug can permanently latch onto through a covalent bond, locking KRAS into its inactive state [8]. Calderasib exploits this same cysteine hook. It binds irreversibly to the mutant KRAS G12C protein and traps it in the GDP-bound (off) conformation, shutting down the downstream growth signals through the RAF-MEK-ERK pathway [6]. The triple-combination rationale in KANDLELIT-012 stacks three attacks: calderasib shuts off KRAS signaling directly, cetuximab blocks EGFR (a receptor upstream of KRAS that can reactivate growth signaling through bypass routes), and mFOLFOX6 chemotherapy kills dividing cells through DNA damage [1]. This upstream-plus-downstream blockade addresses a known problem with KRAS G12C inhibitors in CRC: colorectal tumors are less responsive to KRAS inhibition alone than lung cancers, partly because CRC cells can reactivate EGFR-driven feedback loops that NSCLC cells typically cannot [9].

KANDLELIT-012 (NCT06997497) is a Phase 3, randomized, open-label trial enrolling approximately 462 patients with previously untreated, KRAS G12C-mutant, locally advanced unresectable or metastatic colorectal cancer [1]. The experimental arm receives calderasib orally once daily plus cetuximab every two weeks plus mFOLFOX6 every two weeks. The comparator arm receives mFOLFOX6 with or without bevacizumab - the current first-line standard of care for KRAS-mutant CRC. The primary endpoint is progression-free survival. The with-or-without bevacizumab design in the control arm introduces analytical complexity: oncologists are split on bevacizumab use in first-line KRAS-mutant mCRC, and patients receiving bevacizumab may have modestly longer PFS than those without it, creating a heterogeneous control that could add noise to the primary endpoint comparison or dilute a treatment effect if the bevacizumab subgroup performs well. This is a smart design for several reasons. First, the comparator reflects actual clinical practice: bevacizumab plus FOLFOX is the backbone most oncologists reach for in first-line KRAS-mutant mCRC. Second, testing in the first-line setting avoids the enrollment challenges of chemo-refractory trials where patients are scarce and sick. Third, the combination addresses the CRC-specific biology: EGFR blockade with cetuximab would normally be contraindicated in KRAS-mutant disease (because mutant KRAS bypasses EGFR), but a KRAS G12C inhibitor that turns off the mutant protein should restore EGFR sensitivity, making cetuximab useful again [9]. Whether the trial excludes RAS-pathway co-mutations such as BRAF V600E or PIK3CA - which could affect KRAS inhibitor sensitivity and trial generalizability - has not been disclosed in the publicly available protocol summary. The Phase 1 data supporting this design showed a confirmed ORR of 38% (95% CI 21-58) and an unconfirmed ORR of 66% (95% CI 46-82) for the calderasib-cetuximab-mFOLFOX6 triplet in patients with zero to one prior lines of therapy (n=29), though median follow-up was only 4.6 months [6]. In previously treated patients, the cetuximab doublet achieved a confirmed ORR of 46% (n=39, median follow-up 9.2 months) and monotherapy achieved 38% confirmed ORR (n=53, median follow-up 23.2 months) [6]. Note that the Phase 1 triplet cohort included patients with up to one prior line, whereas KANDLELIT-012 enrolls only treatment-naive patients - the Phase 3 population is slightly more favorable, which may improve on the Phase 1 signal.

Our model puts this drug's chances of eventual approval at 38%. That figure starts from the historical approval rate for Phase 3 drugs in this area - about 57% - then gets adjusted up or down based on ten facts about the trial and sponsor. The biggest boosts come from the sponsor's strong approval track record and more secondary endpoints than usual; the biggest drags are weak earlier-phase results and a randomized trial design. The remaining factors were close to average and didn't shift the estimate much either way.

Efficacy risk is the biggest concern. In CRC, KRAS G12C inhibitors consistently perform worse than in lung cancer. Sotorasib monotherapy managed only 9.7% ORR in chemo-refractory CRC (6/62 patients in CodeBreak 100) [13], and even the approved sotorasib-panitumumab combination delivered 26% ORR with median PFS of 5.6 months in CodeBreaK 300 [9][10]. This appears to be biology, not pharmacology: CRC cells maintain active EGFR-driven feedback loops that reactivate growth signaling even when KRAS is blocked [9]. The triplet combination in KANDLELIT-012 attempts to solve this with cetuximab, but whether that fully overcomes the resistance remains unproven beyond early-phase data. Safety risk is moderate but nontrivial for a three-drug regimen. KRAS G12C inhibitors as a class cause GI toxicity (diarrhea, nausea) and hepatotoxicity. Layering cetuximab (acneiform rash, hypomagnesemia) and mFOLFOX6 (neuropathy, myelosuppression) on top creates a toxicity burden that could limit dose intensity or drive discontinuation, particularly in older CRC patients. In Phase 1, treatment-related adverse events were reported in 97% of triplet patients versus 58% on monotherapy [15]. Execution risk centers on the small addressable population: KRAS G12C mutations occur in only 3-4% of all mCRC cases, meaning molecular screening across many patients is needed to enroll each one [7]. Competitive timing risk is underappreciated. KRYSTAL-10, Mirati/BMS's Phase 3 trial of adagrasib plus cetuximab in second-line KRAS G12C mCRC, is expected to read out in 2026 [16]. If positive, it would establish the KRAS G12C inhibitor plus anti-EGFR paradigm as a post-chemotherapy standard potentially two years before KANDLELIT-012 reports first-line data. Calderasib's differentiation would then rest primarily on the first-line setting and the chemotherapy backbone - a harder commercial proposition against an entrenched competitor with multi-year oncologist familiarity. Sotorasib-panitumumab already carries a similar head start in post-chemo CRC [2]. Intellectual property risk cannot be assessed: calderasib's patent composition and expected exclusivity timeline have not been publicly disclosed, a meaningful gap for investor horizon analysis given Merck's broader Keytruda patent cliff dynamics. Commercial risk is real even if the trial succeeds. Merck would be selling a biomarker-selected targeted therapy to a fraction of a fraction of CRC patients, and payer pushback on triple-combination pricing for a small-population indication is predictable.

Worth watching - upgraded from the prior score but not yet top-tier signal. KANDLELIT-012 is a well-designed trial from a capable sponsor, testing in the right setting (first-line), with the right combination rationale. The corrected PoS of ~62% reflects validated target biology and strong biomarker selection that the prior model underweighted. But calderasib is a third-mover in an increasingly crowded KRAS G12C space: sotorasib and adagrasib are approved, divarasib showed 62% ORR with cetuximab in Phase 1b [11], and multiple next-generation KRAS inhibitors are advancing. Merck's competitive advantage is not the molecule - it's the platform. Combining calderasib with Keytruda (in NSCLC) and with cetuximab-chemo (in CRC) shows Merck using its portfolio breadth. The NSCLC program (KANDLELIT-004/007) is the one to watch more closely: a 77% ORR with calderasib plus pembrolizumab in treatment-naive PD-L1 TPS ≥1% NSCLC is a standout number [14][15]. For CRC specifically, two near-term catalysts to monitor: (1) KRYSTAL-10 readout in 2026, which will clarify whether the KRAS G12C plus anti-EGFR paradigm clears Phase 3 in CRC at all [16]; and (2) KANDLELIT-012 enrollment completion and interim analysis timing, likely mid-2027. The key data point that would upgrade this from 'monitor' to 'signal' is confirmed PFS exceeding 8-9 months in the triplet arm - enough to clearly beat both the bevacizumab-chemo standard and the sotorasib-panitumumab benchmark. One gap in long-term modeling: calderasib's patent and exclusivity timeline has not been disclosed. Merck's 2025 revenue of $64.2 billion means this program, while small in absolute market terms, fits a broader KRAS franchise play across tumor types [12].